EIF2A and pancreatic adenocarcinoma: Sustained eIF2α phosphorylation was linked with a poor prognosis, higher risk of metastasis, and lower disease-free survival of patients with prostate cancer [56,64], PDAC [57], pancreatic adenocarcinoma (PAAD) [65], hepatocellular carcinoma (HCC) [66], and brain tumors [67].